PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA

• U. Vitolo,
• G. S. Nowakowski,
• J. M. Burke,
• C. P. Fox,
• M. Trneny,
• A. Chiappella,
• M. Waldron-Lynch,
• N. Hadar,
• A. Pachori,
• G. Lenz

Affiliations

U. Vitolo

1 Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Italy

G. S. Nowakowski

2 Division of Hematology, Mayo Clinic, Rochester

J. M. Burke

3 Department of Hematology, US Oncology Research and Rocky Mountain Cancer Centers, Aurora, United States of America

C. P. Fox

4 Department of Clinical Hematology, Nottingham University Hospitals NHS, Nottingham, United Kingdom

M. Trneny

5 1st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czechia

A. Chiappella

6 Division of Hematology & Stem Cell Transplant, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy

M. Waldron-Lynch

7 MorphoSys US, Boston, United States of America

N. Hadar

7 MorphoSys US, Boston, United States of America

A. Pachori

7 MorphoSys US, Boston, United States of America

G. Lenz

8 Department of Medicine A – Haematology and Oncology, University Hospital Münster, Münster, Germany